Ardelyx to Report Second Quarter 2016 Financial Results on August 8th, 2016

USA Profile Username: jon@newsinnovations.com / edit profile Ardelyx to Report Second Quarter 2016 Financial Results on August 8th, 2016 PR Newswire FREMONT, Calif., Aug. 1, 2016 FREMONT, Calif., Aug. 1, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that it will report second quarter 2016 financial results after market close on Monday, August 8, 2016. Following the announcement, the Ardelyx management team will host a live conference call and webcast at 4:30pm ET to review the Company's financial results and provide a business update. The live webcast can be accessed by visiting the investor section of Ardelyx's website at ir.ardelyx.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 1-855-296-9612 (US) or 920-663-6277 (International) to listen to the conference call. The conference ID number for the live call will be 56269341. Following the webcast, an archived version of the call will be available until August 22, 2016. About Ardelyx Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. Ardelyx has developed a proprietary drug discovery and design platform enabling it, in a rapid and cost-efficient manner, to discover and design novel drug candidates. Utilizing this platform, Ardelyx has discovered and designed tenapanor, which it is evaluating for the treatment of irritable bowel syndrome with constipation (IBS-C) and for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis. In addition to tenapanor, Ardelyx is developing RDX227675, a non-absorbed polymer for the treatment of hyperkalemia, or high potassium, a problem prevalent in patients with kidney and heart disease.  Ardelyx is also advancing several research programs focused in GI and cardio-renal diseases. Ardelyx is located in Fremont, California. For more information, please visit Ardelyx's website at www.ardelyx.com. Logo - http://photos.prnewswire.com/prnh/20140619/119451   SOURCE Ardelyx CONTACT: Investor and Media: Mark Kaufmann, Chief Financial Officer, mkaufmann@ardelyx.com, 510-745-1751; Investors: Bill Slattery, Jr., Burns McClellan on behalf of Ardelyx, bslattery@burnsmc.com, 212-213-0006 Web Site: http://www.ardelyx.com Follow Us To change the settings for your profile(s) or email delivery, go to https://prnmedia.prnewswire.com/profile/?action=editProfile and select the profile you would like to edit. You can select the industries, subjects, languages, geographical areas, companies, delivery options and delivery frequencies of your choice. In addition to current press releases, you can also find archived news, corporate information, photos, tradeshow news and much more on the PR Newswire for Journalists website: https://prnmedia.prnewswire.com To contact us, email: mediasite@prnewswire.com Please do not reply to this email; this is an automatically generated message. Copyright © PR Newswire Association LLC. All Rights Reserved. A UBM plc company. Our mailing address is: 350 Hudson Street, Suite 300 New York, NY 10014-4504